ARTICLE | Clinical News
RGN-259: Phase II started
January 3, 2011 8:00 AM UTC
RegeneRx said independent investigators began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 2 drops of RGN-259 given 6 times daily for 28 days in about 20 patients. ...